Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Maréchal, Raphaël ^a   De Schutter, Jef ^b   Nagy, Nathalie ^a   Demetter, Pieter ^a   Lemmers, Arnaud ^a   Devière, Jacques ^a   Salmon, Isabelle ^a   Tejpar, Sabine ^c   Van Laethem, Jean Luc ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ACTIVITY; CELL INFILTRATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; ADENOCARCINOMA; CANCER STAGING; COLORECTAL TUMOR; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954054889     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-340     Document Type: Article

References (44)

1. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 2005, 41:107-27. 10.1358/dot.2005.41.2.882662, 15821783.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345. 10.1056/NEJMoa033025, 15269313.
3. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208. 10.1200/JCO.2004.10.182, 14993230.
4. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. N Eng J Med 2009, 2:1408-17.
5. Bokemeyer C, Bondarenko I, Makhson, et al. Fluorouracil,leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-71. 10.1200/JCO.2008.20.8397, 19114683.
6. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-9. 10.1200/JCO.2007.12.5906, 18202412.
7. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-5. 10.1158/0008-5472.CAN-06-0191, 16618717.
8. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19:508-15. 10.1093/annonc/mdm496, 17998284.
9. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005, 6:279-286. 10.1016/S1470-2045(05)70102-9, 15863375.
10. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study. Clin Cancer Res 2008, 14:5869-5876. 10.1158/1078-0432.CCR-08-0449, 18794099.
11. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-45. 10.1200/JCO.2007.11.5956, 17664472.
12. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-7. 10.1200/JCO.2006.10.5437, 17664471.
13. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007, 25:3930-3935. 10.1200/JCO.2007.11.5022, 17761976.
14. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-45. 10.1038/sj.bjc.6604009, 2360431, 17940504.
15. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5668-70. 10.1200/JCO.2008.18.0786, 19001346.
16. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-9. 10.1200/JCO.2008.20.2796, 19398573.
17. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007, 39:271-278. 10.1007/s12026-007-0073-4, 17917071.
18. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-61. 10.1158/1078-0432.CCR-06-1726, 17332301.
19. Hara M, Nakanishi H, Tsujimura K, et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci 2008, 99:1471-8. 10.1111/j.1349-7006.2008.00821.x, 18422755.
20. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-8. 10.1200/JCO.2006.08.8021, 17704420.
21. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-1129. 10.1200/JCO.2008.18.0463, 19164213.
22. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-92. 10.1200/JCO.2008.18.7229, 19064967.
23. Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunothe 2007, 56:48-59. 10.1007/s00262-006-0160-8.
24. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006, 214:229-238. 10.1111/j.1600-065X.2006.00445.x, 17100888.
25. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005, 175:4180-83.
26. Raoul JL, Van Laethem JL, Peeters M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009, 9:112. 10.1186/1471-2407-9-112, 2678147, 19366444.
27. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25:5225-32. 10.1200/JCO.2007.13.2183, 18024868.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16. 10.1093/jnci/92.3.205, 10655437.
29. Heo DS, Park JG, Hata K, Day R, Herberman RB, Whitesite T. Evaluation of Tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 1990, 50:3681-3690.
30. Van de Losdrecht A. Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study. J Immunol Methods 1991, 141:15-22. 10.1016/0022-1759(91)90205-T, 1865120.
31. Cartron G, Dacheux L, Salles G, Solal-Celigny P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIIa gene. Blood 2002, 99:754-758. 10.1182/blood.V99.3.754, 11806974.
32. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947. 10.1200/JCO.2003.05.013, 12975461.
33. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957, 18347005.
34. Carson WE, Parihar R, Lindemann MJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001, 31:3016-25. 10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J, 11592078.
35. Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3 + T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med 1985, 162:2089-106. 10.1084/jem.162.6.2089, 2187997, 2415663.
36. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006, 29:388-97. 10.1097/01.cji.0000203081.43235.d7, 16799334.
37. Stockmeyer B, Beyer T, Neuhuber W, et al. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 2003, 171:5124-9.
38. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006, 94:259-67. 10.1038/sj.bjc.6602930, 2361112, 16404427.
39. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-54. 10.1182/blood-2002-02-0469, 12393572.
40. Barriere J, Fischel J, Formento P, et al. Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation. ASCO Annual Meeting 2009, e14583.
41. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993, 23:1098-1104. 10.1002/eji.1830230518, 8477804.
42. Schleypen JS, Baur N, Kammerer R, et al. Cytotoxic markers and frequency predict functionnal capacity of natural killer cells infiltrating renal carcinoma. Clin Cancer Res 2006, 12:718-25. 10.1158/1078-0432.CCR-05-0857, 16467081.
43. Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 Bright CD16 - cells and display an impaired capability to kill tumor cells. Cancer 2008, 112:863-75. 10.1002/cncr.23239, 18203207.
44. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing Her2. Clin Cancer Res 2004, 10:5650-5655. 10.1158/1078-0432.CCR-04-0225, 15355889.